Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03763942 · ClinicalTrials.gov registry record · NA
HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)
A NA study of HIV Infections, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 658
- Enrollment target
- 3
- Study locations
NCT03763942: Completed NA study of HIV Infections, sponsored by Emory University.
NCT03763942 is a NA study of HIV Infections that has completed, run by Emory University. The registered enrollment target is 658 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (48% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03763942, a NA study of HIV Infections, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 658 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a randomized controlled clinical trial of a theoretically based mobile app, HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) to prevent human immunodeficiency virus (HIV). Participants in the intervention arm will receive access to the HealthMindr app, with information about PrEP and other HIV prevention methods in addition to provider locators. Participants randomized to the control arm will receive standard of care. The primary aim for this study is to assess PrEP uptake in the intervention arm compared to the control arm.
Primary Outcome
PrEP uptake was assessed at each follow-up timepoint (3, 6, 9, and 12 months) in the intervention and control groups. The primary measure of PrEP uptake will be self-report. Validation will occur through submission of a dried blood spot self-collection kit to detect tenofovir diphosphate (TFV-DP) and/or upload of a photo of a PrEP prescription bottle.
Conditions Studied
Interventions
- BEHAVIORAL HealthMindr App
- BEHAVIORAL Control App
Study Locations (3)
District of Columbia
- George Washington University - Washington D.C.
Georgia
- Emory University - Atlanta
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2023-03-17 |
| Phase | NA |
What the finished NCT03763942 record still lists
NCT03763942 is an interventional study that assigns participants to a tested intervention. The registered 658 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (48% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which HealthMindr App is the first listed.
NCT03763942 reports a single indexed study location in District of Columbia, Georgia, Mississippi.
Frequently Asked Questions
What is clinical trial NCT03763942 about?
NCT03763942 is a clinical study titled "HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)". This study is a randomized controlled clinical trial of a theoretically based mobile app, HealthMindr, to increase pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) to prevent human immunodeficiency virus (HIV). Participants in the intervention arm will receive access to t...
What is the current status of trial NCT03763942?
This trial is currently completed. It is a NA study. The enrollment target is 658 participants. The study started on 2020-01-28. Estimated completion is 2023-03-17.
What conditions does trial NCT03763942 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT03763942?
The interventions under investigation include: HealthMindr App (BEHAVIORAL), Control App (BEHAVIORAL).
Who is sponsoring clinical trial NCT03763942?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03763942 being conducted?
This trial has 3 study locations across District of Columbia, Georgia, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03763942's enrollment target sits among peer trials
658 46th of 542 higher than 497 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI